Rivaroxaban for preventing adverse outcomes after acute management of acute coronary
KEYWORDS: rivaroxaban, patients, aspirin, treatment, committee, coronary, company, acute, erg, trial, acute coronary, syndrome, coronary syndrome, events, dose

and benefits of continuing treatment with rivaroxaban and extension of treatment beyond 12 months should be done on an individual patient basis as experience up to 24 months is limited. The Committee concluded that it was appropriate that a formal assessment of whether to continue treatment should be made no later than 12 months after starting rivaroxaban. 5 Implementation 5.1 Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of publication. 5.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final draft guidance. 5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the
